[
    "{\"step_by_step_thinking\": \"Tofacitinib is mentioned in multiple documents as a Janus kinase (JAK) inhibitor. For instance, Document [0] states that tofacitinib was the first JAK inhibitor approved for the treatment of rheumatoid arthritis. It was initially thought to be a selective JAK3 inhibitor, but later was found to be a potent inhibitor of JAK1 and JAK2. Therefore, tofacitinib is a JAK inhibitor.\", \"answer_choice\": \"A. yes\"}"
]